# US 2012/0252035 A1 · GDF-15 and/or Troponin T for Predicting Kidney Failure in Heart Surgery Patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252035 A1
- Document ID: US20120252035A1
- Status: Published application
- Kind: A1
- Application number: 13/525,330
- Filed: 2012-06-17
- Published: 2012-10-04
- Earliest claimed: 2009-12-18
- Assignees: Roche Diagnostics Operations, Inc.
- Inventors: Andrea Horsch; Dietmar Zdunek; Georg Hess
- Web page: https://patentgrep.com/patent/US20120252035A1

## CPC

- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- C07K 14/4716: {Muscle proteins, e.g. myosin, actin}
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2333/4712: Muscle proteins, e.g. myosin, actin, protein
- G01N 2333/495: Transforming growth factor [TGF]
- G01N 2333/52: Assays involving cytokines
- G01N 2800/347: Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to the field of laboratory diagnostics. Specifically, means and methods are disclosed for determining a patient's risk of suffering from acute kidney injury after a surgical procedure based on the detection of GDF-15, troponin T and/or a natriuretic peptide.

## Claims

### Claim 1

A method for predicting a risk of acute kidney injury (AKI) in a patient subjected to a surgical procedure, comprising:
a) contacting, in vitro, a sample obtained from the patient before the patient undergoes the surgical procedure with a ligand comprising specific binding affinity for GDF-15;
b) determining the amount of GDF-15 in the sample; and
c) providing a prediction that the patient is not at risk of AKI if the amount of GDF-15 is below about 1078 pg/ml, or that the patient has an increased risk of AKI if the amount of GDF-15 is above about 1717 pg/ml.

### Claim 2 (depends on 1)

The method of claim 1, wherein the surgical procedure is orthopedic surgery, a tumor resection, surgery of the gastrointestinal tract not involving tumor resection, or cardiac surgery.

### Claim 3 (depends on 1)

The method of claim 1, wherein the ligand comprising specific binding affinity for GDF-15 is an antibody, nucleic acid, receptor, binding partner, or aptamer.

### Claim 4 (depends on 1)

The method of claim 1, wherein the amount of GDF-15 in the sample is determined by measuring a signal obtained from GDF-15, wherein the intensity of the signal directly correlates with the number of molecules of GDF-15 in the sample.

### Claim 5 (depends on 1)

The method of claim 1, wherein the amount of GDF-15 in the sample is determined by measuring a signal obtained from a secondary component, wherein the intensity of the signal indirectly correlates with the number of molecules of GDF-15 in the sample.

### Claim 6 (depends on 1)

The method of claim 1, wherein the patient is predicted to have an increased risk of AKI requiring hemodialysis if the amount of GDF-15 is above about 2573 pg/ml.

### Claim 7 (depends on 1)

The method of claim 1, further comprising contacting, in vitro, the sample obtained from the patient before the patient undergoes the surgical procedure with a second ligand comprising specific binding affinity for troponin T; determining the amount of troponin T in the sample; and providing a prediction that the patient is not at risk of AKI if the amount of GDF-15 is below about 1078 pg/ml and the amount of troponin T is below about 13.3 pg/ml, or that the patient has an increased risk of AKI if the amount of GDF-15 is above about 1717 pg/ml and the amount of troponin T is above about 25.5 pg/ml.

### Claim 8 (depends on 1)

The method of claim 1, further comprising contacting, in vitro, the sample obtained from the patient before the patient undergoes the surgical procedure with a second ligand comprising specific binding affinity for NT-proBNP; determining the amount of NT-proBNP in the sample; and providing a prediction that the patient is not at risk of AKI if the amount of GDF-15 is below about 1078 pg/ml and the amount of NT-proBNP is below about 488.2 pg/ml, or that the patient has an increased risk of AKI if the amount of GDF-15 is above about 1717 pg/ml and the amount of NT-proBNP is above about 1118.7 pg/ml.

### Claim 9 (depends on 1)

The method of claim 1, further comprising contacting, in vitro, the sample obtained from the patient before the patient undergoes the surgical procedure with a second ligand comprising specific binding affinity for troponin T and a third ligand comprising specific binding affinity for NT-proBNP; determining the amounts of troponin T and NT-proBNP in the sample; and providing a prediction that the patient is not at risk of AKI if the amount of GDF-15 is below about 1078 pg/ml, the amount of troponin T is below about 13.3 pg/ml, and the amount of NT-proBNP is below about 488.2 pg/ml; or that the patient has an increased risk of AKI if the amount of GDF-15 is above about 1717 pg/ml, the amount of troponin T is above about 25.5 pg/ml, and the amount of NT-proBNP is above about 1118.7 pg/ml.

### Claim 10

A method for predicting a risk of acute kidney injury (AKI) in a patient subjected to a surgical procedure, comprising:
a) contacting, in vitro, a sample obtained from the patient after the patient undergoes the surgical procedure with an antibody immunoreactive for GDF-15;
b) determining the amount of GDF-15 in the sample; and
c) providing a prediction that the patient is not at risk of AKI if the amount of GDF-15 is below about 1807 pg/ml and that the patient has an increased risk of AKI if the amount of GDF-15 is above about 3389 pg/ml.

### Claim 11 (depends on 10)

The method of claim 10, wherein the surgical procedure is orthopedic surgery, a tumor resection, surgery of the gastrointestinal tract not involving tumor resection, or cardiac surgery.

### Claim 12 (depends on 10)

The method of claim 10, wherein the sample is obtained from the patient immediately after surgery or less than 1 day, 2 days, or 3 days after the patient undergoes the surgical procedure.

### Claim 13 (depends on 10)

The method of claim 10, wherein the ligand comprising specific binding affinity for GDF-15 is an antibody, nucleic acid, receptor, binding partner, or aptamer.

### Claim 14 (depends on 10)

The method of claim 10, wherein the amount of GDF-15 in the sample is determined by measuring a signal obtained from GDF-15, wherein the intensity of the signal directly correlates with the number of molecules of GDF-15 in the sample.

### Claim 15 (depends on 10)

The method of claim 10, wherein the amount of GDF-15 in the sample is determined by measuring a signal obtained from a secondary component, wherein the intensity of the signal indirectly correlates with the number of molecules of GDF-15 in the sample.

### Claim 16 (depends on 10)

The method of claim 10, wherein the patient is predicted to have an increased risk of AKI requiring hemodialysis if the amount of GDF-15 is above about 6393 pg/ml.

### Claim 17 (depends on 10)

The method of claim 10, further comprising contacting, in vitro, the sample obtained from the patient after the patient undergoes the surgical procedure with a second ligand comprising specific binding affinity for troponin T; determining the amount of troponin T in the sample; and providing a prediction that the patient is not at risk of AKI if the amount of GDF-15 is below about 1807 pg/ml and the amount of troponin T is below about 312.4 pg/ml, or that the patient has an increased risk of AKI if the amount of GDF-15 is above about 3389 pg/ml and the amount of troponin T is above about 503.6 pg/ml.

### Claim 18 (depends on 10)

The method of claim 10, further comprising contacting, in vitro, the sample obtained from the patient after the patient undergoes the surgical procedure with a second ligand comprising specific binding affinity for NT-proBNP; determining the amount of NT-proBNP in the sample; and providing a prediction that the patient is not at risk of AKI if the amount of GDF-15 is below about 1807 pg/ml and the amount of NT-proBNP is below about 368.6 pg/ml, or that the patient has an increased risk of AKI if the amount of GDF-15 is above about 3389 pg/ml and the amount of NT-proBNP is above about 924.6 pg/ml.

### Claim 19 (depends on 10)

The method of claim 10, further comprising contacting, in vitro, the sample obtained from the patient after the patient undergoes the surgical procedure with a second ligand comprising specific binding affinity for troponin T and a third ligand comprising specific binding affinity for NT-proBNP; determining the amounts of troponin T and NT-proBNP in the sample; and providing a prediction that the patient is not at risk of AKI if the amount of GDF-15 is below about 1807 pg/ml, the amount of troponin T is below about 312.4 pg/ml, and the amount of NT-proBNP is below about 368.6 pg/ml; or that the patient has an increased risk of AKI if the amount of GDF-15 is above about 3389 pg/ml, the amount of troponin T is above about 503.6 pg/ml, and the amount of NT-proBNP is above about 924.6 pg/ml.

### Claim 20

A device for predicting a risk of acute kidney injury (AKI) in a patient subjected to a surgical procedure, comprising:
a) an analyzing unit comprising means for contacting, in vitro, a sample obtained from the patient before or after the patient undergoes the surgical procedure with a ligand comprising specific binding affinity for GDF-15, and means for determining the amount of GDF-15 in the sample; and
b) an evaluation unit comprising a computer for comparing the determined amount of GDF-15 with a reference amount, predicting the risk of AKI during or immediately after the surgical procedure, and providing an output indicating the risk of AKI.
